|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US5525464A
(en)
|
1987-04-01 |
1996-06-11 |
Hyseq, Inc. |
Method of sequencing by hybridization of oligonucleotide probes
|
|
US6054270A
(en)
|
1988-05-03 |
2000-04-25 |
Oxford Gene Technology Limited |
Analying polynucleotide sequences
|
|
US5700637A
(en)
|
1988-05-03 |
1997-12-23 |
Isis Innovation Limited |
Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays
|
|
US5871928A
(en)
|
1989-06-07 |
1999-02-16 |
Fodor; Stephen P. A. |
Methods for nucleic acid analysis
|
|
US5744101A
(en)
|
1989-06-07 |
1998-04-28 |
Affymax Technologies N.V. |
Photolabile nucleoside protecting groups
|
|
US5800992A
(en)
|
1989-06-07 |
1998-09-01 |
Fodor; Stephen P.A. |
Method of detecting nucleic acids
|
|
US5143854A
(en)
|
1989-06-07 |
1992-09-01 |
Affymax Technologies N.V. |
Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
|
|
DE69233087T2
(de)
|
1991-11-22 |
2003-12-24 |
Affymetrix, Inc. (N.D.Ges.D.Staates Delaware) |
Verfahren zur Herstellung von Polymerarrays
|
|
US5807522A
(en)
|
1994-06-17 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for fabricating microarrays of biological samples
|
|
US5795716A
(en)
|
1994-10-21 |
1998-08-18 |
Chee; Mark S. |
Computer-aided visualization and analysis system for sequence evaluation
|
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
RU2319693C9
(ru)
|
1999-01-13 |
2008-08-20 |
Байер Копэрейшн |
Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
|
|
US20020065296A1
(en)
|
1999-01-13 |
2002-05-30 |
Bayer Corporation |
Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
EP1140840B1
(en)
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US7141581B2
(en)
|
1999-07-02 |
2006-11-28 |
Agouron Pharmaceuticals, Inc. |
Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
|
|
TWI262914B
(en)
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
|
PL203782B1
(pl)
|
1999-11-05 |
2009-11-30 |
Astrazeneca Ab |
Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
|
|
PT1255536E
(pt)
|
1999-12-22 |
2006-09-29 |
Sugen Inc |
Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
|
|
DE122008000002I1
(de)
|
2000-02-15 |
2008-04-17 |
Sugen Inc |
Pyrrol substituierte indolin-2-on protein kinase inhibitoren
|
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ATE345130T1
(de)
|
2001-12-03 |
2006-12-15 |
Bayer Pharmaceuticals Corp |
Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
|
|
SE0104164L
(sv)
|
2001-12-11 |
2003-06-12 |
Ericsson Telefon Ab L M |
Högspännings-mos-transistor
|
|
NO317200B1
(no)
|
2002-08-09 |
2004-09-13 |
Best Practice Deployment As |
System for trafikkopplaering i et kjoretoy
|
|
NZ538982A
(en)
|
2002-09-27 |
2008-07-31 |
Oridis Biomed Forschungs Und E |
Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer
|
|
EP2003196A3
(en)
*
|
2003-06-09 |
2009-01-07 |
The Regents of the University of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
EP2392565B1
(en)
|
2003-09-26 |
2014-03-19 |
Exelixis, Inc. |
c-Met modulators and methods of use
|
|
GB0411378D0
(en)
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
|
WO2006138275A2
(en)
|
2005-06-13 |
2006-12-28 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing cancer
|
|
CN101506351A
(zh)
*
|
2005-10-21 |
2009-08-12 |
拜尔健康护理有限责任公司 |
用于癌症预测和预后及监测癌症治疗的方法
|
|
WO2007053573A2
(en)
|
2005-10-31 |
2007-05-10 |
Bayer Pharmaceuticals Corporation |
Treatment of cancer with sorafenib
|
|
US8329408B2
(en)
|
2005-10-31 |
2012-12-11 |
Bayer Healthcare Llc |
Methods for prognosis and monitoring cancer therapy
|
|
US20080213374A1
(en)
|
2006-07-10 |
2008-09-04 |
Elan Pharma International Limited |
Nanoparticulate sorafenib formulations
|
|
CN101541977A
(zh)
*
|
2006-09-19 |
2009-09-23 |
诺瓦提斯公司 |
用于raf抑制剂的靶向调节、效力、诊断和/或预后的生物标志物
|
|
ES2670423T3
(es)
|
2007-07-25 |
2018-05-30 |
Eisai R&D Management Co., Ltd. |
Inhibidores de multicinasas para uso en el tratamiento de cáncer
|
|
US20090062368A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched sunitinib
|
|
US20090062347A1
(en)
|
2007-08-29 |
2009-03-05 |
Protia, Llc |
Deuterium-enriched axitinib
|
|
CA2698795C
(en)
|
2007-09-10 |
2016-04-19 |
Cipla Limited |
Process for the preparation of a raf kinase inhibitor and intermediates for use in the process
|
|
WO2009041621A1
(ja)
|
2007-09-26 |
2009-04-02 |
Chugai Seiyaku Kabushiki Kaisha |
抗il-6レセプター抗体
|
|
WO2009054004A2
(en)
|
2007-10-22 |
2009-04-30 |
Natco Pharma Limited |
Process for the preparation of sorafenib
|
|
EP2253629A1
(en)
|
2007-11-21 |
2010-11-24 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of racemic sunitinib malate, compositions containing them and preparation thereof
|
|
US20100256392A1
(en)
|
2007-11-21 |
2010-10-07 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of sunitinib base and processes for preparation thereof
|
|
US20110112164A1
(en)
|
2008-02-21 |
2011-05-12 |
Generics (Uk) Limited |
Novel polymorphs and processes for their preparation
|
|
WO2009106825A1
(en)
|
2008-02-27 |
2009-09-03 |
Cipla Limited |
Polymorphs of sorafenib and salts thereof
|
|
EP2098521A1
(en)
|
2008-03-06 |
2009-09-09 |
Ratiopharm GmbH |
Crystal forms of N-[2-(diethylamino) ethyl]-5-[fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrolle-3-carboxamide and methods for their prepparation
|
|
EP2142507A1
(en)
|
2008-03-06 |
2010-01-13 |
Sicor, Inc. |
Process for the preparation of sorafenib and salts thereof
|
|
EP2274303B1
(en)
|
2008-03-31 |
2012-08-29 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing sunitinib and salts thereof
|
|
US8501962B2
(en)
|
2008-06-23 |
2013-08-06 |
Natco Pharma Limited |
Process for the preparation of high purity sunitinib and its pharmaceutically acceptable salt
|
|
US8618309B2
(en)
|
2008-07-24 |
2013-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sunitinib and salts thereof and their polymorphs
|
|
WO2010036796A1
(en)
|
2008-09-26 |
2010-04-01 |
Concert Pharmaceuticals, Inc. |
Pyridineamine derivatives
|
|
WO2010039798A2
(en)
|
2008-09-30 |
2010-04-08 |
Teva Pharmaceutical Industries Ltd. |
Amorphous compositions of sunitinib base and l-malic acid
|
|
JP5439494B2
(ja)
|
2008-10-21 |
2014-03-12 |
バイエル ヘルスケア エルエルシー |
肝細胞癌と関連するシグネチャ遺伝子の同定
|
|
EP2181991A1
(en)
|
2008-10-28 |
2010-05-05 |
LEK Pharmaceuticals D.D. |
Novel salts of sunitinib
|
|
WO2013022995A2
(en)
*
|
2011-08-08 |
2013-02-14 |
Caris Life Sciences Luxembourg Holdings, S.A.R.L. |
Biomarker compositions and methods
|
|
EP2186809A1
(en)
|
2008-11-13 |
2010-05-19 |
LEK Pharmaceuticals D.D. |
New crystal form of sunitinib malate
|
|
EP2366162A1
(en)
*
|
2008-11-18 |
2011-09-21 |
Collabrx, Inc. |
Individualized cancer treatment
|
|
WO2010135608A1
(en)
|
2009-05-20 |
2010-11-25 |
Nodality, Inc. |
Methods for diagnosis, prognosis and methods of treatment
|
|
WO2011004200A1
(en)
|
2009-07-10 |
2011-01-13 |
Generics [Uk] Limited |
Novel pyrrole derivatives
|
|
KR20120049267A
(ko)
|
2009-07-16 |
2012-05-16 |
글락소 웰컴 매뉴팩쳐링 피티이 엘티디 |
치료 방법
|
|
WO2011039648A1
(en)
|
2009-09-30 |
2011-04-07 |
Glaxo Wellcome Manufacturing Pte Ltd. |
Methods of administration and treatment
|
|
EP2470212A4
(en)
|
2009-10-01 |
2013-12-04 |
Csl Ltd |
METHOD FOR TREATING POSITIVE PHILADELPHIA CHROMOSOME LEUKEMIA
|
|
US20120245051A1
(en)
|
2009-10-13 |
2012-09-27 |
Rimm David L |
Objective, quantitative method to predict histological subtype in non-small cell lung cancer
|
|
EP2490536A4
(en)
|
2009-10-23 |
2013-04-17 |
Glaxo Wellcome Mfg Pte Ltd |
COMPOSITION AND METHOD
|
|
TW201201808A
(en)
|
2010-01-06 |
2012-01-16 |
Glaxo Wellcome Mfg Pte Ltd |
Treatment method
|
|
WO2011100325A2
(en)
|
2010-02-09 |
2011-08-18 |
Sicor Inc. |
Polymorphs of sunitinib salts
|
|
WO2011104555A2
(en)
|
2010-02-25 |
2011-09-01 |
Generics [Uk] Limited |
Novel process
|
|
WO2011128699A2
(en)
|
2010-04-16 |
2011-10-20 |
Generics [Uk] Limited |
Novel process
|
|
TW201206908A
(en)
|
2010-05-05 |
2012-02-16 |
Glaxo Wellcome Mfg Pte Ltd |
Pharmaceutical compositions and methods of making same
|
|
WO2011146458A1
(en)
|
2010-05-18 |
2011-11-24 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
CA2816559C
(en)
|
2010-11-01 |
2018-02-13 |
Scinopharm (Kunshan) Biochemical Technology Co., Ltd. |
Processes for the preparation of 3-((pyrrol-2-yl)methylene)-2-pyrrolones using 2-silyloxy-pyrroles
|
|
WO2012073254A1
(en)
|
2010-11-29 |
2012-06-07 |
Hetero Research Foundation |
A process for the preparation of pazopanib using novel intermediate
|
|
US10220020B2
(en)
|
2010-12-23 |
2019-03-05 |
Nektar Therapeutics |
Polymer-des-ethyl sunitinib conjugates
|
|
WO2012103060A1
(en)
|
2011-01-27 |
2012-08-02 |
Glaxo Wellcome Manufacturing Pte Ltd |
Method of administration and treatment
|
|
WO2012116040A1
(en)
*
|
2011-02-22 |
2012-08-30 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
|
CN102283836B
(zh)
|
2011-06-27 |
2013-01-09 |
苏州大学附属第一医院 |
索拉非尼在制备治疗动脉瘤性自发性蛛网膜下腔出血后发生的早期脑损伤的药物中的应用
|
|
US20140235678A1
(en)
|
2011-06-28 |
2014-08-21 |
Bayer Healthcare Llc |
Topical Ophthalmological Pharmaceutical Composition containing Sorafenib
|
|
WO2013043529A1
(en)
|
2011-09-19 |
2013-03-28 |
Emory University |
Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto
|
|
WO2013046133A1
(en)
|
2011-09-30 |
2013-04-04 |
Pfizer Inc. |
Pharmaceutical compositions of n-methyl-2-[3-((e)-2-pyridin-2-yl-vinyl)-1h-indazol-6-ylsulfanyl]-benzamide
|
|
WO2013090419A1
(en)
|
2011-12-12 |
2013-06-20 |
Stc.Unm |
Gene expression signatures for detection of underlying philadelphia chromosome-like (ph-like) events and therapeutic targeting in leukemia
|
|
US20140087362A1
(en)
*
|
2012-03-16 |
2014-03-27 |
Aladar A. Szalay |
Methods for assessing effectiveness and monitoring oncolytic virus treatment
|
|
US11136625B2
(en)
|
2013-08-28 |
2021-10-05 |
Crown Bioscience, Inc. (Taicang) |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|